September 13th, 2022 marks the 11th World Sepsis Day. It was established by the Global Sepsis Alliance and other founders like WFSICCM and WFPICCS to raise awareness about sepsis and get more support from healthcare policymakers. 

As a leading hemoperfusion technology provider, Jafron has always advocated for sepsis prevention and treatment development, proactively working on methods to provide patients with more access to efficient treatment.

Copyright photo from https: https://ammi.ca/en/event/world-sepsis-day/

About Sepsis

According to recent research published in the Lancet, it is estimated that there are about 49 million sepsis cases globally, and about 11 million people die from it, accounting for 20% of all deaths worldwide. Sepsis is the body's extreme response to an infection, which is life-threatening because of its potential to cause tissue damage, organ failure, and death. When not treated timely, it can lead to severe complications, including septic shock, a fatal condition that happens when the blood pressure drops to a dangerously low level after an infection.

In most cases, patients will experience the following symptoms:

1. High heart rate or weak pulse

2. Confusion or disorientation

3. Extreme pain or discomfort

4. Fever, shivering, or feeling very cold

5. Shortness of breath

6. Clammy or sweaty skin

Common sepsis treatment can be divided into medications, supportive care, and surgery. In this aspect, Jafron has also made its contribution.

Jaron's Contribution to Sepsis Treatment

Studies have shown that treating patients suffering from severe sepsis with continuous hemoperfusion can remove bodies' metabolic waste, toxins, reducing the inflammatory reaction and improving vascular tension and hemodynamic stability. Therefore, it shows a positive effect accompanied by other regular methods like mechanical ventilation and fluid resuscitation. 

Much research on the effect of hemoperfusion has been carried on, and the results are approved by many professors and experts. Dr. Franz Schwameis, chief of Anesthesia and Intensive Care in LK Baden, acclaimed that "hemoperfusion is a powerful adjunct therapy. It might positively affect outcomes and save lives if used early."    

HA380 and HA330 Disposable Hemoperfusion Cartridges, produced by Jafron, are CE-labeled adsorption cartridges developed to treat patients with septic shock. According to clinical practices and studies, HA380 and HA330 cartridges are indicated to remove the following substances:

1) Inflammatory cytokines including IL-1, IL-6, IL-8, IL-10, TNF-α

2) Excessive triglyceride and cholesterol in hyperlipidemia severe acute pancreatitis

3) Other substances: bilirubin, myoglobin, overdosed drugs

Currently, it has been applied in countries in the Middle East and Asia, and now are stepping into European counties with more and more patients getting in touch with Jafron hemoperfusion devices. 

Conclusion

It takes time and effort to raise public awareness of the prevention and treatment of sepsis, and needless to say, it requires help from medical experts' further education. And Jafron will always in the front line to help more people to master the acute phase.

Reference

[1] What is sepsis? Available at: https://www.cdc.gov/sepsis/what-is-sepsis.html

[2] What is septic shock? Available at: 

https://www.nhsinform.scot/illnesses-and-conditions/blood-and-lymph/septic-shock

[3] The reasons why sepsis is hard to spot. Available at:

https://www.bbc.com/news/health-35409266

[4] HA380 in sepsis treatment, available at:

https://clinicaltrials.gov/ct2/show/NCT04997421